Breast Neoplasms Clinical Trials in St Louis, Missouri

8 studies are recruiting for breast neoplasms in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

   Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Washington University Siteman Cancer Center ( Site 0031), St Louis, Missouri

   Locations

   325 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06966700 on ClinicalTrials.gov

2. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

   The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colore…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University, St Louis, Missouri

   Locations

   33 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07114601 on ClinicalTrials.gov

3. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

   This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713.…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University School of Medicine in St. Louis, St Louis, Missouri

   Locations

   30 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07213791 on ClinicalTrials.gov

4. A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

   This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant and another treatment to suppress their ovarian function. S…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   89 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07287098 on ClinicalTrials.gov

5. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

   The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally ad…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Washington University School of Medicine ( Site 0076), St Louis, Missouri

   Locations

   259 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06312176 on ClinicalTrials.gov

6. Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

   The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test re…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mercy Health - Sindelar Cancer Center, St Louis, Missouri

   Locations

   49 in total

   Run by

   Natera, Inc.

   See if you can join NCT07214532 on ClinicalTrials.gov

7. Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

   Multiple neoadjuvant endocrine trials demonstrate that women with good prognosis tumors can be identified. These trials have also demonstrated that there are not adverse effects on overall outcome if women are treated with neoadjuvant endocrine therapy for several months prior to definitive treatme…

   Stage

   Phase 2

   Ages

   70 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT02476786 on ClinicalTrials.gov

8. Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

   The main purpose of this study is to compare genetic markers present on tumor cells before and after chemotherapy.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT00353483 on ClinicalTrials.gov